Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor. An aromatase inhibitor is hormone therapy that lowers the chance of breast cancer coming back (recurring) after surgery by blocking an enzyme in fat tissue called aromatase; aromatase changes other hormones in the body to estrogen. Women who do not complete the standard 5-year treatment are at higher risk of their cancer coming back. The goal of this research is to prevent breast cancer from coming back after surgery by helping women to stay on treatment with

Trial Details

NCT ID
NCT07071038
Phase
PHASE2
Sponsor
Dartmouth-Hitchcock Medical Center
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Switch
  • Guideline Directed Intervention (GDI)
Locations (sample)
  • Lebanon, New Hampshire, United States|43.64229,-72.25176

Key Eligibility Criteria

  • Histologic documentation of DCIS or invasive breast cancer by core needle or incisional biopsy.
  • The DCIS or invasive cancer must be estrogen receptor alpha (ER)-positive
  • The invasive cancer must be HER2-negative (IHC 0-1+, or with a FISH ratio of \<1.8 if IHC is 2+ or if IHC has not been done)
  • Clinical Stage I-III invasive breast cancer or DCIS

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →